Rallybio Profit Margin

The latest profit margin for RLYB is 7051.24% as of June 2026. That compares with -5473.32% in the prior-year period — up 228.8% year over year. That is above the Healthcare sector average of 13.89%. Investors often review this figure alongside Rallybio's historical trend and sector peers before judging valuation or financial health.

Over the past year, RLYB's profit margin moved from -5473.32% to 7051.24% — a 228.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Rallybio's valuation or profitability profile.

Against Healthcare companies, RLYB currently prints 7051.24% for profit margin, while the sector average sits near 13.89%. That is roughly 50664.3% above the sector mean. Large gaps often invite a closer look at Rallybio's growth, margins, and balance sheet.

Profit Margin shows how effectively Rallybio converts resources into returns. At 7051.24%, RLYB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -5473.32% in the prior-year period — up 228.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RLYB's profit margin (7051.24%), review year-over-year change from -5473.32%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.